Original articleLamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial
Introduction
Schizophrenia severely affects quality of life and causes huge direct and indirect costs in industrialized countries as a consequence of its chronic and persistent symptomatology. When antipsychotic drugs are used to manage the symptoms, less than half of schizophrenic patients reach full remission, and 20% to 60% of the patients who receive conventional dopamine antagonist neuroleptics continue to have ongoing symptoms (Kane 1989). Clozapine has been established as the drug of choice for the treatment of those patients who are resistant to treatment with conventional neuroleptic drugs Kane et al 1988, Kane 1996. Although clozapine is considered the most efficient of known antipsychotic drugs, about half of the patients achieve only a poor or partial response with it Kane et al 1988, Tollefson et al 2001. For this reason, anticonvulsant augmentation treatments, such as valproic acid, have been widely used, although no data from controlled studies have been published to demonstrate their beneficial effectiveness.
Lamotrigine is a novel anticonvulsant drug, which has a mechanism of action based on the sodium (Na+)-channel antagonism and the inhibition of excessive glutamate release in the brain Cousin et al 1993, Grunze et al 1998, Leach et al 1991, and a large amount of evidence implicates dysfunctional glutamatergic neurotransmission in the pathophysiology of schizophrenia (for a review, see Goff and Coyle 2001). Therefore, lamotrigine is a potential treatment for schizophrenia. In two previous studies, lamotrigine in combination with clozapine was observed to be very effective in reducing symptoms measured with the Brief Psychiatric Rating Scale (BPRS) among patients with schizophrenia in open trials Dursun et al 1999, Dursun and Deakin 2001. Recently, lamotrigine was shown to be markedly superior to placebo in reducing BPRS positive symptoms induced by ketamine in healthy volunteers (Anand et al 2000). On the basis of these findings, it was decided to test whether or not lamotrigine would be more effective than placebo when combined with clozapine in treating positive symptoms of patients with schizophrenia.
Section snippets
Patients
The study protocol was approved by the ethical committee of Kuopio University Hospital. Sixty-eight patients fulfilling the inclusion criteria in the preliminary screen were selected from Niuvanniemi Hospital, Kuopio, Finland (a high-security state mental hospital that treats mentally ill criminals and treatment-resistant patients). On the basis of the results of two previous open trials Dursun et al 1999, Dursun and Deakin 2001, the sufficient sample size was estimated to be 30 patients in
Results
The 34 patients included in the study did not differ substantially from the 32 patients who refused to participate when measured by GAF (37.50 ± 8.49 vs. 40.34 ± 9.43, p > .2, t = 1.29, df = 64, Student t test). The 16 patients who received lamotrigine during the first period did not differ statistically from the 18 patients who first received placebo, according to any of their demographic and clinical characteristics, which are shown in Table 1 (p ≥ .10, Student t test). The progress of all
Discussion
These results indicate that lamotrigine combined with clozapine is more effective in the treatment of positive and general psychopathological symptoms than clozapine alone among patients with treatment-resistant schizophrenia. In the correlation analysis, there was a tendency suggesting that the beneficial effect was slightly greater among those patients who had a shorter duration of illness and who were the most resistant to clozapine treatment (having high PANSS positive symptom scores). Our
Acknowledgements
The study was supported by funding from Annual EVO Financing (Special government subsidies). No support was provided by any pharmaceutical company. We thank Mrs. Tarja Mehtonen, Ms. Aija Räsänen, and Ms. Ulla Rautamo for secretarial assistance.
References (43)
- et al.
Flunarizine inhibits both calcium-dependent and independent release of glutamate from synaptosomes and cultured neurones
Brain Res
(1993) - et al.
The glutamate synapse in neuropsychiatric disordersFocus on schizophrenia and Alzheimers disease
Prog Brain Res
(1998) - et al.
A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia
Biol Psychiatry
(1999) - et al.
Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current
Brain Res
(1998) - et al.
Assessing the quality of reports of randomized clinical trialsIs blinding necessary?
Control Clin Trials
(1996) - et al.
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine
Biol Psychiatry
(2001) - et al.
D-serine added to antipsychotics for the treatment of schizophrenia
Biol Psychiatry
(1998) - et al.
Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients
Biol Psychiatry
(1996) Diagnostic and Statistical Manual of Mental Disorders
(1994)- et al.
Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists
Arch Gen Psychiatry
(2000)
Lamotrigine in the treatment of bipolar disorder
Expert Opin Pharmacother
Long-term treatment of bipolar disorder with lamotrigine
J Clin Psychiatry
A coefficient of agreement for nominal scales
Educ Psychol Meas
Statistical Power Analysis for the Behavioral Sciences
Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia
J Neurochem
Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophreniaA naturalistic case-series outcome study
J Psychopharmacol
Clozapine plus lamotrigine in treatment-resistant schizophrenia
Arch Gen Psychiatry
Placebo-controlled trial of glycine added to clozapine in schizophrenia
Am J Psychiatry
The drug-placebo response curveA new method for assessing drug effects in clinical trials
J Clin Psychopharmacol
Structured Clinical Interview for DSM-IV Axis I Disorders—Patient Edition (SCID-I/P, Version 2.0, 4/97 revision)
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia
Am J Psychiatry
Cited by (158)
Glutamate modulators for treatment of schizophrenia
2019, Personalized Medicine in Psychiatry